Amarin Seeks ITC Action Against Products 'Cloaked' As Dietary Supplements

Seeking to protect its competitive interests, Vascepa marketer asks the US International Trade Commission to investigate importation and sale of synthetically produced omega-3 products by 18 companies; complaint asserts the products at issue are unapproved new drugs that are illegally being marketed as dietary supplements.

US International Trade Commission ITC in Washington DC
Amarin seeks ITC review of 18 companies' omega0-3 products.

Two years after successfully suing the US FDA to enable communications about the off-label use of Vascepa (icosapent ethyl), Amarin Corp. PLC is again seeking an unusual route in trying to protect its market for the triglyceride-lowering agent – by asking the International Trade Commission (ITC) to block unapproved drugs "cloaked" as dietary supplements.

Amarin is requesting an ITC investigation "into the unlawful importation or sale" in the US of synthetically produced omega-3 products...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet